Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      Homepharmaceutical stock

      pharmaceutical stock

      Nektar Downgraded by JPMorgan, Blaming Setup Following The Discontinuation Of Its Anti-Cancer Program
      Investing News

      Nektar Downgraded by JPMorgan, Blaming Setup Following The Discontinuation Of Its Anti-Cancer Program

      August 9, 2022
      Eli Lilly And Co SHARES WILL GO EX-DIVIDEND IMMINENTLY BUT SHOULD THIS WORRY SHAREHOLDERS
      Investing News

      Eli Lilly And Co SHARES WILL GO EX-DIVIDEND IMMINENTLY BUT SHOULD THIS WORRY SHAREHOLDERS

      August 8, 2022
      Vertex Improves Revenue Guidance For 2022 Due To Q2 Top And Bottom-Line Gains
      Investing News

      Vertex Improves Revenue Guidance For 2022 Due To Q2 Top And Bottom-Line Gains

      August 5, 2022
      « 1 2

       

      LATEST NEWS

      • Investing News Pfizer Reports Strong Q4 2025 Earnings
      • Investing News Teradyne Q4 Earnings and AI Demand Surge
      • Investing News Nvidia Stock Outlook: AI Dominance Keeps NVDA Strong
      • Investing News AMD Stock Outlook: Bullish Ahead of Q4 Earnings
      • Investing News Disney Parks Q1 Performance Revealed

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026